Table 1 Comparison of clinical and molecular characteristics with miR-25 expression in patients with AML
Characteristic | Chemotherapy group | Allo-HSCT group | ||||
|---|---|---|---|---|---|---|
High miR-25 (n = 45) | Low miR-25 (n = 45) | P | High miR-25 (n = 36) | Low miR-25 (n = 36) | P | |
Age/years, median | 61.4 (22–82) | 64.4 (31–88) | 0.49 | 47.3 (22–72) | 49.4 (18–69) | 0.535 |
Age group/n (%) (years) | Â | Â | 0.495 | Â | Â | 0.793 |
 < 60 | 16 (35.6) | 12 (26.7) |  | 27 (75) | 25 (69.4) |  |
 ≥ 60 | 29 (64.4) | 33 (73.3) |  | 9 (25) | 11 (30.6) |  |
Gender/n (%) | Â | Â | 0.289 | Â | Â | 0.634 |
 Male | 22 (48.9) | 28 (62.2) |  | 22 (61.1) | 19 (52.8) |  |
 Female | 23 (51.1) | 17 (37.8) |  | 14 (38.9) | 17 (47.2) |  |
WBC/× 109/L, median | 32.4 (0.7–297.4) | 51.8 (1.5–298.4) | 0.059 | 36.0 (0.6–223.8) | 39.8 (1.2–118.8) | 0.248 |
BM blast/%, median | 69 (32–99) | 67.2 (30–92) | 0.955 | 66.2 (34–99) | 70.2 (30–100) | 0.277 |
PB blast/%, median | 39.5 (0–98) | 35.1 (0–97) | 0.320 | 46.1 (0–96) | 48.9 (0–94) | 0.752 |
FAB subtypes/n (%) | ||||||
 M0 | 4 (8.9) | 4 (8.9) | 1.000 | 6 (16.7) | 3 (8.3) | 0.478 |
 M1 | 13 (28.9) | 7 (15.6) | 0.204 | 7 (19.4) | 16 (44.4) | 0.042 |
 M2 | 12 (26.7) | 9 (20) | 0.619 | 12 (33.3) | 7 (19.4) | 0.285 |
 M4 | 11 (24.4) | 13 (28.9) | 0.812 | 8 (22.2) | 6 (16.7) | 0.767 |
 M5 | 4 (8.9) | 9 (20) | 0.230 | 2 (5.6) | 2 (5.6) | 1.000 |
 M6 | 1 (2.2) | 0 (0.0) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
 M7 | 0 (0.0) | 2 (4.4) | 0.494 | 1 (2.8) | 0 (0.0) | 1.000 |
 No date | 0 (0.0) | 1 (2.2) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
Karyotype/n (%) | ||||||
 Normal | 18 (40) | 26 (57.8) | 0.140 | 15 (41.7) | 19 (52.7) | 0.479 |
 Complex | 5 (11.1) | 7 (15.6) | 0.758 | 6 (16.6) | 6 (16.6) | 1.000 |
 Poor | 0 (0.0) | 5 (11.1) | 0.056 | 1 (2.8) | 4 (11.1) | 0.357 |
 Intermediate | 8 (17.8) | 2 (4.4) | 0.090 | 6 (16.7) | 3 (8.4) | 0.478 |
 MLL | 1 (2.2) | 2 (4.4) | 1.000 | 3 (8.3) | 0 (0.0) | 0.239 |
 CBFβ-MYH11 | 6 (13.3) | 1 (2.2) | 0.110 | 4 (11.1) | 1 (2.8) | 0.357 |
 BCR-ABL1 | 0 (0.0) | 1 (2.2) | 1.000 | 0 (0.0) | 2 (5.6) | 0.493 |
 RUNX1-RUNX1T1 | 6 (13.3) | 0 (0.0) | 0.026 | 1 (2.8) | 0 (0.0) | 1.000 |
 N.D. | 1 (2.2) | 1 (2.2) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
Risk(cyto)/n (%) | ||||||
 Good | 12 (26.7) | 1 (2.2) | 0.002 | 5 (13.9) | 1 (2.8) | 0.199 |
 Intermediate | 26 (57.8) | 29 (64.4) | 0.665 | 21 (58.3) | 20 (55.5) | 1.000 |
 Poor | 6 (13.3) | 14 (31.1) | 0.074 | 10 (27.8) | 14 (38.9) | 0.454 |
 Other | 1 (2.2) | 1 (2.2) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
FLT3-ITD/n (%) | Â | Â | 0.784 | Â | Â | 0.045 |
 Presence | 9 (20.0) | 7 (15.6) |  | 4 (11.1) | 12 (33.3) |  |
 Absence | 36 (80.0) | 38 (84.4) |  | 32 (88.9) | 24 (66.7) |  |
NPM1/n (%) | Â | Â | 0.175 | Â | Â | 0.064 |
 Presence | 11 (24.4) | 18 (40) |  | 6 (16.7) | 14 (38.9) |  |
 Absence | 34 (75.6) | 27 (60) |  | 36 (83.3) | 22 (61.1) |  |
DNMT3A/n (%) | Â | Â | 0.157 | Â | Â | 1.000 |
 Presence | 9 (20) | 16 (35.6) |  | 9 (25) | 9 (25) |  |
 Absence | 36 (80) | 29 (64.6) |  | 27 (75) | 27 (75) |  |
RUNX1/n (%) | Â | Â | 0.714 | Â | Â | 0.710 |
 Presence | 5 (11.1) | 3 (6.7) |  | 5 (13.9) | 3 (8.3) |  |
 Absence | 40 (89.9) | 42 (93.3) |  | 31 (86.1) | 33 (91.7) |  |
MLL-PTD/n (%) | Â | Â | 1.000 | Â | Â | Â |
 Presence | 2 (4.4) | 3 (6.7) |  | 2 (5.6) | 2 (5.6) |  |
 Absence | 43 (95.6) | 42 (93.3) |  | 34 (94.4) | 34 (94.4) |  |
TP53/n (%) | Â | Â | 0.522 | Â | Â | 1.000 |
 Mutation | 4 (8.9) | 7 (15.6) |  | 2 (5.6) | 2 (5.6) |  |
 Wild type | 41 (91.1) | 38 (84.4) |  | 34 (94.4) | 34 (94.4) |  |
CEBPA/n (%) | Â | Â | 1.000 | Â | Â | 0.055 |
 Mutation | 1 (2.2) | 2 (4.4) |  | 7 (19.4) | 1 (2.8) |  |
 Wild type | 44 (97.8) | 43 (95.6) |  | 29 (80.6) | 35 (97.2) |  |
IDH1/n (%) | Â | Â | 1.000 | Â | Â | 0.514 |
 Mutation | 3 (6.7) | 4 (8.9) |  | 4 (11.1) | 7 (19.4) |  |
 Wild type | 42 (93.3) | 41 (91.1) |  | 32 (88.9) | 29 (80.6) |  |
IDH2/n (%) | Â | Â | 1.000 | Â | Â | 0.260 |
 Mutation | 5 (11.1) | 4 (8.9) |  | 2 (5.6) | 6 (16.7) |  |
 Wild type | 40 (88.9) | 41 (91.1) |  | 34 (94.4) | 30 (83.3) |  |